A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: August 2025
By Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY 2026 Appropriations & Congressional Recess: A Vital Advocacy Window As Congress continues its August recess, this “district and state … Continued
Researchers Discover Potential Therapeutic Targets for Low-Grade Serous Ovarian Cancer
Scientists have identified sixteen potential therapeutic targets in low-grade serous ovarian cancer by studying proteins at the molecular level, with results published on August 11, 2025, in the journal Cancer … Continued
OCRA’s Advocate’s Corner: July 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget & Appropriations Update: Approaching August with Focused Advocacy As Congress advances the FY 2026 appropriations process, gynecologic cancer advocates … Continued